Similar Search Results

Management of Acute Otitis Media: Defining the Role of Cefuroxime Axetil

Lamb, Harriet M.; Spencer, Caroline M. - In: Disease Management and Health Outcomes 8 (2000) 6, pp. 337-353

Growing concern about the rapid emergence of penicillin-resistant Streptococcus pneumoniae, as well as beta … example is the recommendations of the US Drug-Resistant S. pneumoniae (DRSP) Therapeutic Working Group which advocate an …: Cefuroxime axetil is one of very few oral agents which has proven clinical efficacy against S. pneumoniae, as well as beta …

Persistent link: https://www.econbiz.de/10005404604

Antibacterials and Acute Exacerbation of Chronic Bronchitis: Issues for Formulary Decision Makers

Chock, Alan; Gong, Vera; Destache, Christopher J. - In: Disease Management and Health Outcomes 10 (2002) 6, pp. 333-336

The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related …

Persistent link: https://www.econbiz.de/10005404640

Threshold Analysis of Helicobacter pylori Therapy

Sonnenberg, Amnon - In: PharmacoEconomics 14 (1998) 4, pp. 423-432

Objective: Conflicting recommendations have been made on whom to treat with antibacterials to eradicate Helicobacter … choosing one type of therapy over another, a trial of antibacterials appears indicated irrespective of any firm validation of H …

Persistent link: https://www.econbiz.de/10005404790

Socioeconomics of a Global Leprosy Eradication Programme

Naik, Sharad S.; Ganapati, Ramaswamy - In: PharmacoEconomics 13 (1998) 6, pp. 677-686

In the absence of evidence in the literature on cost factors in the management of leprosy, a reference is made to the sporadic attempts to study costs of case detection and treatment. Such studies indicate that in the currently declining phase of leprosy endemicity, employing a conventionally...

Persistent link: https://www.econbiz.de/10005404853

Economic Evaluation of Ciprofloxacin Compared with Usual Antibacterial Care for the Treatment of Acute Exacerbations of Chronic Bronchitis in Patients Followed for 1 Year

Torrance, George; Walker, Valery; Grossman, Ronald; … - In: PharmacoEconomics 16 (1999) 5, pp. 499-520

Objective: To undertake a 1-year prospective economic evaluation of ciprofloxacin compared with usual antibacterial care (any antibacterial other than a quinolone) for the treatment of acute exacerbations of chronic bronchitis (AECB) in adults presenting with a type I or type II AECB. Design:...

Persistent link: https://www.econbiz.de/10005404991

The Annual Cost of Chronic Obstructive Pulmonary Disease to the UK's National Health Service

Guest, Julian F. - In: Disease Management and Health Outcomes 5 (1999) 2, pp. 93-100

Objective: The objective of this study was to estimate the annual resource use and corresponding costs (at 1996/97 prices) to the UK's National Health Service (NHS) arising from the management of chronic obstructive pulmonary disease (COPD). Design and Setting: A subgroup analysis was performed...

Persistent link: https://www.econbiz.de/10005590095

Antibacterials for Viral Respiratory Infections: Results of a Physician-Based Intervention in a Predominantly Preferred Provider Organization Setting

Berthiaume, John; Chernicoff, Helen O.; Kim, Jaok J.; … - In: Disease Management and Health Outcomes 11 (2003) 10, pp. 663-671

the inappropriate prescribing of antibacterials, and managed care organizations can use claims-based, episode …

Persistent link: https://www.econbiz.de/10005590194

Meropenem: A Pharmacoeconomic Review of its Use in Serious Infections

Holliday, Stephen M.; Benfield, Paul - In: PharmacoEconomics 13 (1998) 3, pp. 359-377

Meropenem is a carbapenem antibiotic which is active against the majority of aerobic and anaerobic bacteria implicated in serious infections. Its therapeutic efficacy in a wide range of serious infections is similar to that of imipenem/cilastatin and standard combination drug regimens. Hence,...

Persistent link: https://www.econbiz.de/10005590296

Cost Comparison of Antibacterial Therapies for Serious Infections: A New Zealand 3-Hospital Study

Scott, W. Guy; Scott, Helen M.; Henderson, Seton; … - In: PharmacoEconomics 16 (1999) 2, pp. 183-192

360 patient-treatment days and 8 antibacterials. Main outcome measures and results: Drug acquisition cost ranged from 4 …

Persistent link: https://www.econbiz.de/10005590387

Piperacillin/Tazobactam in Moderate to Severe Bacterial Infections The full text of this article was published in PharmacoEconomics 2001; 19 (11): 1135-1175.

Young, Melissa; Plosker, Greg L. - In: Disease Management and Health Outcomes 10 (2002) 3, pp. 195-199

-acquired pneumonia. Piperacillin/tazobactam plus amikacin had lower total costs than ceftazidime plus amikacin in another cost analysis … tobramycin was more costly than ceftazidime plus tobramycin in hospital-acquired pneumonia in a US cost analysis. In cost …-effectiveness analyses, all studies of intra-abdominal infections, pneumonia and febrile neutropenic episodes consistently reported lower …

Persistent link: https://www.econbiz.de/10005448843